Nivolumab in combination for treating hormone-relapsed metastatic prostate cancer before chemotherapy [ID1619]
Discontinued
Reference number: GID-TA10490
The Department for Health and Social Care has asked NICE to conduct an appraisal of nivolumab in combination for treating hormone-relapsed metastatic prostate cancer before chemotherapy [ID1619]
The company have advised that they will not be pursuing a Marketing Authorisation Application for nivolumab from the European Medicines Authority for this indication at this time. Therefore, NICE has decided to suspend this appraisal on its work programme.
As this appraisal has been referred, NICE will continue to monitor the situation and update interested parties if the situation changes.